Crystalline inclusion complexes formed between the drug diflunisal and block copolymers

被引:16
作者
Zhong, Zhi [1 ]
Yang, Xiaotong [1 ]
Fu, Xiao-Bin [2 ]
Yao, Ye-Feng [2 ]
Guo, Bao-Hua [1 ]
Huang, Yanbin [1 ]
Xu, Jun [1 ]
机构
[1] Tsinghua Univ, Dept Chem Engn, Key Lab Adv Mat MOE, Beijing 100084, Peoples R China
[2] East China Normal Univ, Sch Phys & Mat Sci, Inst Funct Mat, Shanghai Key Lab Magnet Resonance, Shanghai 200062, Peoples R China
基金
中国国家自然科学基金;
关键词
Pharmaceutical solid forms; Inclusion complexes; Drugs; Block copolymers; Thermal stability; Aqueous solubility; Dissolution profiles; OXIDE) TRIBLOCK COPOLYMERS; SOLID-STATE; PHARMACEUTICAL COCRYSTALS; ALPHA-CYCLODEXTRIN; CHEMICAL-SHIFTS; SOLUBILITY; POLY(ETHYLENE; DISCOVERY; COMPOUND; POLYMERS;
D O I
10.1016/j.cclet.2017.04.001
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
The solid form of drugs plays a central role in optimizing the physicochemical properties of drugs, and new solid forms will provide more options to achieve the desirable pharmaceutical profiles of drugs. Recently, certain drugs have been found to form crystalline inclusion complexes (ICs) with multiple types of linear polymers, representing a new subcategory of pharmaceutical solids. In this study, we used diflunisal (DIF) as the model drug host and extended the guest of drug/polymer ICs from homopolymers to block copolymers of poly(ethylene glycol) (PEG) and poly(epsilon-caprolactone) (PCL). The block length in the guest copolymers showed a significant influence on the formation, thermal stability and dissolution behavior of the DIF ICs. Though the PEG block could hardly be included alone, it could indeed be included in the DIF ICs when the PCL block was long enough. The increase of the PCL block length produced IC crystals with improved thermal stability. The dissolution profiles of DIF/block copolymer ICs exhibited gradually decreased aqueous solubility and dissolution rate with the increasing PCL block length. These results demonstrate the possibility of using drug/polymer ICs to modulate the desired pharmaceutical profiles of drugs in a predictable and controllable manner. (C) 2017 Chinese Chemical Society and Institute of Materia Medica, Chinese Academy of Medical Sciences. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:1268 / 1275
页数:8
相关论文
共 42 条
  • [1] Solubility of sparingly-soluble ionizable drugs
    Avdeef, Alex
    [J]. ADVANCED DRUG DELIVERY REVIEWS, 2007, 59 (07) : 568 - 590
  • [2] Solubility Advantage of Amorphous Drugs and Pharmaceutical Cocrystals
    Babu, N. Jagadeesh
    Nangia, Ashwini
    [J]. CRYSTAL GROWTH & DESIGN, 2011, 11 (07) : 2662 - 2679
  • [3] CRYSTAL STRUCTURE OF POLY-ETA-CAPROLACTONE
    BITTIGER, H
    MARCHESSAULT, RH
    NIEGISCH, WD
    [J]. ACTA CRYSTALLOGRAPHICA SECTION B-STRUCTURAL CRYSTALLOGRAPHY AND CRYSTAL CHEMISTRY, 1970, B 26 (DEC15): : 1923 - +
  • [4] Pharmaceutical cocrystals: walking the talk
    Bolla, Geetha
    Nangia, Ashwini
    [J]. CHEMICAL COMMUNICATIONS, 2016, 52 (54) : 8342 - 8360
  • [5] Supramolecular Aggregation of Block Copolymers in the Solid State As Assisted by the Selective Formation of Inclusion Crystals
    Bracco, Silvia
    Comotti, Angiolina
    Ferretti, Lisa
    Sozzani, Piero
    [J]. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2011, 133 (23) : 8982 - 8994
  • [6] Self-assembly of 1,4-cis-polybutadiene and an aromatic host to fabricate nanostructured crystals by CH•••π interactions
    Bracco, Silvia
    Comotti, Angiolina
    Valsesia, Patrizia
    Beretta, Mario
    Sozzani, Piero
    [J]. CRYSTENGCOMM, 2010, 12 (08): : 2318 - 2321
  • [7] A whole output strategy for polymorph screening: Combining crystal structure prediction, graph set analysis, and targeted crystallization experiments in the case of diflunisal
    Cross, WI
    Blagden, N
    Davey, RJ
    Pritchard, RG
    Neumann, MA
    Roberts, RJ
    Rowe, RC
    [J]. CRYSTAL GROWTH & DESIGN, 2003, 3 (02) : 151 - 158
  • [8] Pharmaceutical cocrystals: along the path to improved medicines
    Duggirala, Naga K.
    Perry, Miranda L.
    Almarsson, Oern
    Zaworotko, Michael J.
    [J]. CHEMICAL COMMUNICATIONS, 2016, 52 (04) : 640 - 655
  • [9] Drugs as materials:: Valuing physical form in drug discovery
    Gardner, CR
    Walsh, CT
    Almarsson, Ö
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (11) : 926 - 934
  • [10] The 1:1 hydrate of diflunisal
    Hansen, LK
    Perlovich, GL
    Brandl, AB
    [J]. ACTA CRYSTALLOGRAPHICA SECTION E-CRYSTALLOGRAPHIC COMMUNICATIONS, 2001, 57 : O477 - O479